{"filing":{"accession_number":"0001493152-26-030286","cik":"0001610820","ticker":"BCTXZ","company_name":"BriaCell Therapeutics Corp.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226030286/form8-k.htm"},"events":[{"id":14219,"run_id":12647,"accession_number":"0001493152-26-030286","anchor_item_number":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The filing discloses unaudited condensed interim consolidated financial statements and MD\u0026A for BriaPro Therapeutics Corp. (a subsidiary of BriaCell) for the nine-month period ended April 30, 2026, filed under Item 7.01 (Regulation FD Disclosure). The financial statements reveal a pre-clinical biotech company with accumulated losses of $1.89M, a shareholders' deficit of $989.7K, and explicit going-concern language noting \"material uncertainty\" about the company's ability to continue operations. While the statements are unaudited and filed under Item 7.01 (not Item 2.02), the disclosure of interim financial results with going-concern doubt is material to investors. This is classified as financial_other rather than going_concern because the primary event is the disclosure of interim financial statements; the going-concern language is embedded within the statements rather than being the standalone focus of the 8-K.","company_name":"BriaCell Therapeutics Corp.","ticker":"BCTXZ","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":11584,"accession_number":"0001493152-26-030286","item_number":null,"item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses unaudited condensed interim consolidated financial statements and MD\u0026A for BriaPro Therapeutics Corp. (a subsidiary of BriaCell) for the nine-month period ended April 30, 2026, filed under Item 7.01 (Regulation FD Disclosure). The financial statements reveal a pre-clinical biotech company with accumulated losses of $1.89M, a shareholders' deficit of $989.7K, and explicit going-concern language noting \"material uncertainty\" about the company's ability to continue operations. While the statements are unaudited and filed under Item 7.01 (not Item 2.02), the disclosure of interim financial results with going-concern doubt is material to investors. This is classified as financial_other rather than going_concern because the primary event is the disclosure of interim financial statements; the going-concern language is embedded within the statements rather than being the standalone focus of the 8-K.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:10:02.244694+00:00","company_name":"BriaCell Therapeutics Corp.","ticker":"BCTXZ","filing_date":"2026-06-26"}]}